Pfizer handed back to Indevus Pharmaceuticals, the development and commercialization rights to pagoclone (Panex®), a partial GABA receptor agonist, in development for the treatment of anxiety disorders. Pfizer stated that the drug did not achieve expected levels of efficacy in clinical trials.